QVAR REDIHALER Drug Patent Profile

Which patents cover Qvar Redihaler, and when can generic versions of Qvar Redihaler launch?

Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. There are seventeen patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qvar Redihaler

A generic version of QVAR REDIHALER was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QVAR REDIHALER

International Patents:	278
US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
Drug Prices:	Drug price information for QVAR REDIHALER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QVAR REDIHALER
What excipients (inactive ingredients) are in QVAR REDIHALER?	QVAR REDIHALER excipients list
DailyMed Link:	QVAR REDIHALER at DailyMed

See drug prices for QVAR REDIHALER

Recent Clinical Trials for QVAR REDIHALER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SGS S.A.	Phase 1
Chiesi Farmaceutici S.p.A.	Phase 1

See all QVAR REDIHALER clinical trials

Pharmacology for QVAR REDIHALER

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for QVAR REDIHALER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QVAR REDIHALER	Inhalation Aerosol	beclomethasone dipropionate	80 mcg/actuation	207921	1	2024-07-31
QVAR REDIHALER	Inhalation Aerosol	beclomethasone dipropionate	40 mcg/actuation	207921	1	2023-10-30

US Patents and Regulatory Information for QVAR REDIHALER

QVAR REDIHALER is protected by seventeen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	12,296,089		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	11,583,643		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	10,561,808		Y		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-001	Aug 3, 2017		RX	Yes	Yes	11,395,889		Y		Y

Expired US Patents for QVAR REDIHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-001	Aug 3, 2017	6,446,627
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017	6,446,627
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017	7,637,260
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-001	Aug 3, 2017	7,637,260

International Patents for QVAR REDIHALER

When does loss-of-exclusivity occur for QVAR REDIHALER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

Portugal

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QVAR REDIHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011254958
Brazil	112012029106
Canada	2799625
Canada	2887315

QVAR REDIHALER (beclomethasone dipropionate) Market Dynamics and Financial Trajectory: Growth Drivers, Share Shifts, Exclusivity Timeline, and Generic/Biosimilar Risk

Last updated: July 30, 2026

QVAR REDIHALER is a beclomethasone dipropionate (BDP) inhaled corticosteroid (ICS) used for asthma maintenance. Its market outcome is driven by (1) substitution dynamics between inhaled corticosteroids (including other BDP products and other ICS classes), (2) payor and formulary positioning versus competing controller therapies, (3) channel inventory and seasonal respiratory demand, and (4) patent and regulatory timing that governs generic entry risk for the REDIHALER platform. The financial trajectory is tied to net sales durability of ICS controller categories, offset by ongoing competitive pressure from alternative controller inhalers and generic availability within the broader beclomethasone ecosystem.

How is QVAR REDIHALER positioned in the inhaled corticosteroid market and what drives share?

What category dynamics shape QVAR REDIHALER demand?

QVAR REDIHALER sits in the asthma controller market led by ICS therapies. Key demand drivers for ICS inhalers include:

• Guideline adherence: ICS remains first-line controller therapy in most asthma treatment frameworks, supporting baseline usage.
• Seasonality: sales typically track respiratory virus season, with demand peaks aligned to cold-weather periods in major markets.
• Switching behavior: patients often remain on current controller therapy unless forced by cost, formulary changes, or device tolerability.

What competitive forces most affect QVAR REDIHALER?

• Device substitution: QVAR REDIHALER uses a breath-actuated design (not an HFA metered-dose inhaler). This can reduce coordination barriers for some patients, but payer decisions often prioritize cost per delivered dose and preferred-device coverage.
• Class competition: alternative ICS products and fixed-dose ICS/LABA combinations compete on formulary simplicity and escalation pathways.
• Formulary tiering and rebates: net prices for inhalers depend on contracting. Controller inhalers see frequent step-editing of preferred status.

How do payers typically manage controller asthma formularies?

• Preferred ICS lists: payers often maintain a preferred list for each delivery device category.
• Step-therapy policies: coverage may require prior use of an ICS (or specific ICS) before moving to combination therapy.
• Switch incentives: pharmacy benefit managers often steer toward lower acquisition cost products, including approved generics where available.

What is QVAR REDIHALER’s financial trajectory and revenue exposure to exclusivity and competition?

What do the economics of ICS inhalers imply for trajectory?

Without device-unique protected status over broad claim sets, ICS inhalers typically face:

• Net price erosion after generic availability or when competitors achieve preferred status.
• Volume shifts during formulary transitions, often faster than price declines.
• Inventory cycles: inhaler market players frequently adjust ordering ahead of expected competitive events, which can distort reported sales quarters.

Where is revenue exposure concentrated?

For QVAR REDIHALER specifically, exposure concentrates in:

• U.S. volume and net sales (most relevant for patent and Orange Book-driven entry risk).
• Device-platform perceptions (patients and clinicians may view device usability as an adherence lever).
• Pharmacy benefit plan mix (top payers influence the magnitude and timing of net sales changes).

When does QVAR REDIHALER lose exclusivity, and how does that timing affect sales?

What exclusivity and patent levers govern generic entry risk?

Generic entry depends on two linked timelines:

1. Patent expiration and any “skinny label”/design-around pathways based on what patents are asserted in Paragraph IV challenges.
2. Regulatory exclusivity related to changes in formulation, device, or new product approvals (if any).

Because QVAR REDIHALER is a reformulated/device re-presentation of beclomethasone dipropionate, its exclusivity outcome is determined by the specific patent landscape covering:

• the device and delivery system claims (if present),
• the formulation (if distinct from earlier marketed beclomethasone products), and
• use claims tied to asthma dosing regimens.

How does exclusivity timing translate into a sales step-down pattern?

In inhaled controllers:

• Sales often hold through the “patent fence,” then decline sharply once a first generic entrant achieves distribution and payer uptake.
• Even after legal clearance, uptake depends on formulary changes, switching friction, and pharmacy stocking.

What patents protect QVAR REDIHALER, and how strong is the patent estate?

Which patent types most matter for QVAR REDIHALER?

For inhaled corticosteroids and device-delivered products, the most economically meaningful claims often fall into:

• Formulation patents: particle size, suspension characteristics, stabilizers, and aerosol performance attributes.
• Method-of-use patents: dosing schedules or asthma management regimens.
• Device and delivery system patents: breath-actuated mechanics, actuator structure, and internal flow paths.

How to assess patent strength for litigation and design-around risk

Patent strength in this market is typically evaluated by:

• Expiration concentration: multiple patents expiring in the same window raises entry risk even if some claims remain.
• Claim breadth: broad device claims are harder to design around.
• Assignee and filing strategy: estates anchored by long-filing trends often indicate continued defense of the platform.

What generic entry risks exist for QVAR REDIHALER?

What Paragraph IV scenarios are most common for inhaled steroids?

For QVAR-type inhalers, generic risk scenarios usually include:

• ANDA approval tied to a carve-out of covered strengths or dosing instructions.
• Design-around of device-specific features while preserving therapeutic equivalence.
• Settlement-driven launch sequencing: first filers may get a delayed launch date in exchange for an agreement.

How does first-filer advantage affect market share?

ICS inhalers tend to experience:

• fastest uptake by the first approved generic due to early wholesaler stocking and payer listing,
• subsequent entrants following after additional discounts and formulary updates.

What is the Orange Book status of QVAR REDIHALER?

What Orange Book listings typically signal market timing?

Orange Book entries map to:

• which patents are listed for each strength,
• their expiration dates,
• whether any are “method of use” versus “drug substance or composition.”

Orange Book timing is a primary input for:

• Paragraph IV filing calendars,
• damages exposure modeling,
• settlement timing assumptions.

What FDA and regulatory factors affect QVAR REDIHALER competition?

What FDA pathway dynamics matter for generics?

• ANDA bioequivalence requirements can slow time to approval if formulation or particle/aerosol performance differs.
• If the product involves device performance requirements, applicants may need additional bridging evidence.

How do post-approval changes affect launch feasibility?

Any manufacturing process or device modification can:

• trigger supplemental applications,
• complicate sameness arguments,
• delay generic demonstration of equivalence.

How does QVAR REDIHALER compare with other inhaled corticosteroids on market dynamics?

What are the main competitive benchmarks in asthma controllers?

Benchmarks typically include:

• other BDP products in alternative devices,
• budesonide and fluticasone ICS competitors,
• fixed-dose ICS/LABA combinations that capture escalation patients.

Where does QVAR REDIHALER typically win or lose?

• Wins: patients needing controller therapy with a device that reduces coordination errors; clinicians favoring consistent delivered dosing attributes.
• Loses: formulary preference for lower net cost or “preferred device” programs and step-up therapies that move patients into combination inhalers.

Which companies are challenging QVAR REDIHALER, and what litigation has occurred?

What patent litigation patterns matter most to market share?

Inhaler patent cases often determine:

• whether generic launch is delayed,
• whether a settlement fixes a launch date,
• whether a “carve-out” label limits substitution.

How settlement agreements affect sales

Settlements typically:

• cap legal risk through a defined entry date,
• reduce uncertainty for payers and wholesalers,
• accelerate uptake once cleared.

What commercial metrics should be tracked to model QVAR REDIHALER sales?

High-signal indicators

To forecast revenue path and competitive inflection, track:

• NDC-level prescription trends for QVAR REDIHALER versus ICS competitors.
• Plan coverage changes (preferred status, step edits, PA policies).
• Wholesaler inventory and channel fill around legal timing.
• Net pricing pressure from generic or preferred-brand contracting.

Key Takeaways

• QVAR REDIHALER competes in a high-substitution ICS market where formularies and device preferences often determine net sales outcomes more than clinical differentiation.
• Its financial trajectory is tightly linked to the patent/Orange Book landscape covering the REDIHALER platform, because generic uptake follows patent clearance and payer listing speed.
• Generic entry risk is modeled through (1) patent expiration timing, (2) Paragraph IV litigation/settlement outcomes, and (3) practical barriers to demonstrating product equivalence in aerosol performance and device delivery.
• Sales durability is strongest while it retains preferred payer placement; market share loss typically accelerates after competitors achieve preferred status or generic entries gain distribution.

FAQs

1. How does device usability influence payer and formulary coverage for QVAR REDIHALER versus other ICS inhalers?
2. What are the most common Paragraph IV settlement structures for inhaled corticosteroids like beclomethasone dipropionate?
3. How should investors model net sales decline timing once QVAR REDIHALER exclusivity ends, accounting for formulary switching lag?
4. What NDC-level substitution patterns should be watched when generic beclomethasone inhalers enter the market?
5. How do inhaler aerosol performance considerations affect ANDA approval timelines for BDP-based products?

References

1. Bloomberg Law. Patent and Orange Book litigation and exclusivity resources.
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (QVAR REDIHALER listings and patents).
3. FDA. ANDA regulations and bioequivalence guidance for inhalation products.